Scholarlink

<p>Amphetamine-type stimulants (ATS) represent a major segment of the global drugs of abuse market. Prolintane (1-(1-phenylpentan-2-yl)pyrrolidine), a substituted phenylethylamine ATS, was historically utilized as medication for several therapeutic indications. This study aimed to investigate the metabolic fate and urinary detectability of the three novel derivatives 2-, 3-, and 4-fluoroprolintane, which were recently shown to act as monoamine reuptake inhibitors. Liquid chromatography (LC)-high-resolution (HR) tandem mass spectrometry (MS/MS) was used for tentative identification of metabolites in rat urines (collected over a 24&#xa0;h period following oral administration of 2&#xa0;mg/kg fluoroprolintane isomer, each) or incubations with pooled human liver S9 fraction (1&#xa0;h and 6&#xa0;h, 25 µM fluoroprolintane isomer, each). Isozyme mapping was performed using individual incubations with 11 human phase I monooxygenases. The same rat urines were used for detectability studies using standard urine screening approaches (SUSA) by gas chromatography (GC)-mass spectrometry (MS), LC-ion trap MS, and LC-HRMS/MS. The fluoroprolintanes were extensively metabolized, with a total of 79 metabolites identified. Hydroxylations and subsequent oxidations were primarily mediated by CYP1A2, CYP2B6, CYP2C19, and CYP2D6, while glucuronidation and <i>O</i>-methylation were observed as main follow-up phase II reactions. All three SUSA allowed detection, primarily via metabolites. However, the high degree of metabolic overlap will make isomer differentiation challenging. These findings contribute to a comprehensive risk assessment and provide critical reference data for clinical and forensic laboratories to identify these substances in biological specimens.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metabolic fate and detectability of three novel fluoroprolintane psychostimulants: in vitro and in vivo characterization by hyphenated mass spectrometry

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月25日

查看全文
  • Lea Wagmann,
  • Anica Herter,
  • Michael B. Dybek,
  • Adeboye Adejare,
  • Jason Wallach,
  • Simon D. Brandt,
  • Markus R. Meyer

摘要

Amphetamine-type stimulants (ATS) represent a major segment of the global drugs of abuse market. Prolintane (1-(1-phenylpentan-2-yl)pyrrolidine), a substituted phenylethylamine ATS, was historically utilized as medication for several therapeutic indications. This study aimed to investigate the metabolic fate and urinary detectability of the three novel derivatives 2-, 3-, and 4-fluoroprolintane, which were recently shown to act as monoamine reuptake inhibitors. Liquid chromatography (LC)-high-resolution (HR) tandem mass spectrometry (MS/MS) was used for tentative identification of metabolites in rat urines (collected over a 24 h period following oral administration of 2 mg/kg fluoroprolintane isomer, each) or incubations with pooled human liver S9 fraction (1 h and 6 h, 25 µM fluoroprolintane isomer, each). Isozyme mapping was performed using individual incubations with 11 human phase I monooxygenases. The same rat urines were used for detectability studies using standard urine screening approaches (SUSA) by gas chromatography (GC)-mass spectrometry (MS), LC-ion trap MS, and LC-HRMS/MS. The fluoroprolintanes were extensively metabolized, with a total of 79 metabolites identified. Hydroxylations and subsequent oxidations were primarily mediated by CYP1A2, CYP2B6, CYP2C19, and CYP2D6, while glucuronidation and O-methylation were observed as main follow-up phase II reactions. All three SUSA allowed detection, primarily via metabolites. However, the high degree of metabolic overlap will make isomer differentiation challenging. These findings contribute to a comprehensive risk assessment and provide critical reference data for clinical and forensic laboratories to identify these substances in biological specimens.